# Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

> **NCT07244874** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Tianjin Medical University Cancer Institute and Hospital** · enrollment: 41 (estimated)

## Conditions studied

- TNBC - Triple-Negative Breast Cancer
- PD-L1 Positive

## Interventions

- **DRUG:** Sacituzumab tirumotecan
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT07244874
- **Lead sponsor:** Tianjin Medical University Cancer Institute and Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2028-01-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2025-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07244874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07244874, "Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07244874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*